Site search- 2024.11.8IRFinancial Results for the Six Months ended September 30, 2024 [Japanese GAAP] (non-consolidated)（322KB）
- 2024.11.6PRBrightPath to Present the Preclinical Data of T Cell Engager BP1223 at ASH 2024（74KB）
- 2024.8.9IRFinancial Results for the Three Months ended June 30, 2024 [Japanese GAAP] (non-consolidated)（304KB）
- 2024.6.19IRAnnouncement of Issuance of Series 17 to 19 Moving Strike Warrants, Conclusion of a Warrant Purchase Agreement, and Issuance of Unsecured Bonds (Private Placement Bonds)（600KB）
- 2024.5.10IRFinancial Results for the Fiscal Year ended March 31, 2024 [Japanese GAAP] (non-consolidated)（507KB）
- 2024.3.4IRTopline Results of Phase I Clinical Trial of iPS-NKT in Patients with Relapsed or Refractory Head and Neck Cancer（186KB）
- 2024.2.21PRCollaborative researcher will be presenting at CD1-MR1 2024
- 2024.2.9IRFinancial Results for the Nine Months ended December 31, 2023 [Japanese GAAP] (non-consolidated)（302KB）
- 2024.11.8IRFinancial Results for the Six Months ended September 30, 2024 [Japanese GAAP] (non-consolidated)（322KB）
- 2024.8.9IRFinancial Results for the Three Months ended June 30, 2024 [Japanese GAAP] (non-consolidated)（304KB）
- 2024.6.19IRAnnouncement of Issuance of Series 17 to 19 Moving Strike Warrants, Conclusion of a Warrant Purchase Agreement, and Issuance of Unsecured Bonds (Private Placement Bonds)（600KB）
- 2024.5.10IRFinancial Results for the Fiscal Year ended March 31, 2024 [Japanese GAAP] (non-consolidated)（507KB）
- 2024.3.4IRTopline Results of Phase I Clinical Trial of iPS-NKT in Patients with Relapsed or Refractory Head and Neck Cancer（186KB）
- 2024.2.9IRFinancial Results for the Nine Months ended December 31, 2023 [Japanese GAAP] (non-consolidated)（302KB）